{"schema_version":"secwatch.filing_event.v1","accession":"0001214659-23-012218","form_type":"8-K","ticker":"ALZN","cik":"0001677077","company_name":"Alzamend Neuro, Inc.","filed_at":"2023-09-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.826452+00:00","generated_at":"2026-06-10T22:14:06.853051+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Alzamend Neuro enters ATM equity facility for up to $9.8M with Ascendiant Capital","bullets":["Entered Sales Agreement with Ascendiant Capital Markets for at-the-market issuance of common stock up to $9.8M.","Shares sold from time to time under effective shelf registration statement (File No. 333-273610) declared effective Aug 10, 2023.","Agent will use commercially reasonable efforts; Company sets parameters like number, time, and minimum price.","Either party may terminate agreement at any time upon written notice."],"urls":{"canonical":"https://secwatch.observer/filing/0001214659-23-012218","json":"https://secwatch.observer/filing/0001214659-23-012218.json","markdown":"https://secwatch.observer/filing/0001214659-23-012218.md","text":"https://secwatch.observer/filing/0001214659-23-012218.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1677077/000121465923012218/0001214659-23-012218-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1677077/000121465923012218/z972308k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T22:14:06.853051+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f5e71cb9b991d9d27848601311b6dc26c7a08f34","claim":"Alzamend Neuro, Inc. entered into Sales Agreement with Ascendiant Capital Markets, LLC valued at up to approximately $9.8 million (effective 2023-09-08).","evidence_excerpt":"On September 8, 2023, Alzamend Neuro, Inc. (the “ Company ”) entered into an At-the-Market Issuance Sales Agreement (the “ Sales Agreement ”) with Ascendiant Capital Markets, LLC, as sales agent (the “ Agent ”) to sell shares of its common stock, par value $0.0001 (the “ Common Stock ”), having an aggregate offering price of up to approximately $9.8 million","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1677077/000121465923012218/0001214659-23-012218-index.htm","confidence":1.0,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"atm program"},{"label":"Counterparty","value":"Ascendiant Capital Markets, LLC"},{"label":"Value","value":"up to approximately $9.8 million"},{"label":"Effective","value":"2023-09-08"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}